Wedbush downgraded Zentalis Pharmaceuticals to Neutral from Outperform with a price target of $12, down from $38.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZNTL:
- Zentalis price target lowered to $29 from $50 at Wells Fargo
- Zentalis price target lowered to $46 from $55 at H.C. Wainwright
- Zentalis selloff ‘misses the bigger picture,’ says Oppenheimer
- Zentalis CSO Kevin Bunker to step down, Mark Lackner to succeed
- Zentalis announces updated data from Phase 1 trial of azenosertib
